Anxiogenic Effect of Cholecystokinin in the Dorsal Periaqueductal Gray

Neuropsychopharmacology

Volumn 29, Issue 1, 2004, Pages 101-107

  Netto, Cristina Ferreira ^a   Guimarães, Francisco Silveira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anxiety; CCK receptors; Elevated plus maze; Fos

Indexed keywords

CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ OCTAPEPTIDE; LORGLUMIDE; PD 135158; PROTEIN FOS; SODIUM CHLORIDE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; DISEASE MODEL; DORSAL RAPHE NUCLEUS; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; HYPOTHALAMUS; IMMUNOREACTIVITY; MALE; MAZE TEST; MEDIAN RAPHE NUCLEUS; MICROINJECTION; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SEPTUM NUCLEUS; SUPERIOR COLLICULUS;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; APPETITE DEPRESSANTS; CELL COUNT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; HORMONE ANTAGONISTS; IMMUNOHISTOCHEMISTRY; INDOLES; MALE; MAZE LEARNING; MEGLUMINE; MICROINJECTIONS; NEURONS; PERIAQUEDUCTAL GRAY; PROGLUMIDE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CHOLECYSTOKININ B; SINCALIDE; SUPERIOR COLLICULUS; TIME FACTORS;

EID: 0346057788     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300334     Document Type: Article

References (38)

1. Adamec RE, Shallow T, Budgell J (1997). Blockade of CCK(B), but not CCK(A), receptors before and after the stress of predator exposure prevents lasting increases in anxiety-like behavior: implications for anxiety associated with posttraumatic stress disorder. Behav Neurosci 111: 435-449
2. . Behbehani MM (1995). Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 46: 575-605.
3. Beitz AJ (1995). Periaqueductal gray. In: Paxinos G (ed). The Rat Nervous System 2nd edn Academic Press: San Diego, pp 173-182.
4. Bhatnagar S, Viau V, Chu A, Soriano L, Meijer OC, Dallman MF (2000). A cholecystokinin-mediated pathway to the paraventricular thalamus is recruited in chronically stressed rats and regulates hypothalamic-pituitary-adrenal function. J Neurosci 20: 5564-5573.
5. Bradwejn J, Koszycki D, Cöuetoux Du Tertre A, Bourin M, Palmour R, Ervin F (1992). The cholecystokinin hypothesis of panic and anxiety disorders: a review. J Psychopharmacol 6: 345-351.
6. Bradwejn J, Koszycki D, Cöuetoux Du Tertre A, Van Megen H, Den Boer J, Westenberg H (1994). The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365 260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 51: 486-493.
7. Canteras NS, Goto M (1999). Fos-like immunoreactivity in the periaqueductal gray of rats exposed to a natural predator. NeuroReport 10: 413-418.
8. Costall B, Domeney AM, Hughes J, Kelly ME, Naylor RJ, Woodruff GN (1991). Anxiolytic effects of CCKB antagonists. Neuropeptides 19(Suppl): 65-73.
9. De Belleroche J, Bandopadhyay R, King A, Malcolm ADBK, Premi BP, Rashid A (1990). Regional distribution of cholecystokinin messenger RNA in rat brain during development: quantification and correlation with cholecystokinin immunoreactivity. Neuropeptides 15: 201-212.
10. De Oliveira RW, Del Bel EA, Guimarães FS (2000). Behavioural and c-fos expression changes induced by nitric oxide donors microinjected into the dorsal periaqueductal gray. Brain Res Bull 51: 457-464.
11. Del Bel EA, Guimarães FS (1997). Social isolation increases cholecystokinin mRNA expression in the central nervous system of rats. NeuroReport 8: 3597-3600.
12. Dilenberg RA, McGregor IS (2001). Defensive behavior in rats towards predatory odors: a review. Neurosci Biobehav Rev 25: 597-609.
13. Felicio LF, Mazzini BK, Cacheiro RG, Cruz TN, Florio JC, Nasello AG (2001). Stimulation of either cholecystokinin receptor subtype reduces while antagonists potentiate or sensitise a morphine-induced excitatory response. Peptides 22: 1299-1304.
14. File SE (1992). Behavioural detection of anxiolytic action. In: Elliott JM, Heal DJ, Marsden CA (eds). Experimental Approaches to Anxiety and Depression. John Wiley & Sons: New York, pp 25-44.
15. Fink H, Rex A, Voits M, Voigt JP (1998). Major biological actions of CCK - a critical evaluation of research findings. Exp Brain Res 123: 77-83.
16. Griebel G, Perrault G, Sanger DJ (1997). CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviors. Behav Pharmacol 8: 549-560.
17. Guimarães FS, Carobrez AP, De Aguiar JC, Graeff FG (1991). Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonist AP7 microinjected into the dorsal periaqueductal grey. Psychopharmacology 103: 91-94.
18. Guimaraẽs FS, Russo AS, De Aguiar JC, Ballejo G, Graeff FG (1992). Anxiogenic-like effect of CCK-8 micro-injected into the dorsal periaqueductal grey of rats in the elevated plus maze. In: Dourish CT, Cooper SJ, Iversen SD, Iversen LL (eds). Multiple Cholecystokinin Receptors in the CNS. Oxford Science Publication: Oxford, pp 149-154.
19. Hernandez-Gomez AM, Aguilar-Roblero R, Pérez de La Mora M (2002). Role of cholecystokinin-A and cholecystokinin-B receptors in anxiety. Amino Acids 23: 283-290.
20. Herranz R (2003). Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev 23: 559-605.
21. Lino-de-Oliveira C, Sales AJ, Del Bel EA, Silveira MCL, Guimarães FS (2001). Effects of acute and chronic fluoxetine treatments on restraint stress-induced Fos expression. Brain Res Bull 55: 747-754.
22. Liu H, Chandler S, Beitz AJ, Shipley MT, Behbehani MM (1994). Characterization of the effect of cholecystokinin (CCK) on neurons in the periaqueductal gray of the rat: immunocytochemical and in vivo and in vitro electrophysiological studies. Brain Res 642: 83-94.
23. Lovick TA (2000). Panic disorder - a malfunction of multiple transmitter control systems within the midbrain periaqueductal gray matter? Neuroscientist 6: 48-59.
24. Mercer LD, Beart PM, Home MK, Finkelstein DJ, Carrive P, Paxinos G (1996). On the distribution of cholecystokinin B receptors in monkey brain. Brain Res 738: 313-318.
25. Morgan JI, Curran T (1995). Proto-oncogenes: beyond second messengers. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York, pp 631-642.
26. Pavlasevic S, Bednar I, Qureshi GA, Södersten P (1993). Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety. NeuroReport 5: 225-228.
27. Paxinos G, Watson C (1997). The Rat Brain in Stereotaxic Coordinates 3th edn. Academic Press: New York.
28. Rehfeld JF (2000). Cholecystokinin and panic disorder - three unsettled questions. Reg Peptides 93: 79-83.
29. Rosen A, Brodin K, Eneroth P, Brodin E (1992). Short-term restraint stress and s.c. saline injection alter the tissue levels of substance P and cholecystokinin in the periaqueductal grey and limbic regions of rat brain. Acta Physiol Scand 148: 341-348.
30. Russo AS, Guimarães FS, De Aguiar JC, Graeff FG (1993). Role of benzodiazepine receptors located in the dorsal periaqueductal grey of rats in anxiety. Psychopharmacology 110: 198-202.
31. Sewards TV, Sewards MA (2002). Fear and power-dominance motivation neural representation and pathways mediating sensory and mnemonic inputs and outputs to premotor structures. Neurosci Biobehav Rev 26: 553-579.
32. Shipley MT, Ennis M, Rizvi TA, Behbehani MM (1991). Topographical specificity of forebrain inputs to the midbrain periaqueductal gray: evidence for discrete longitudinally organized input columns. In: Depaulis A, Bandler R (eds). The Midbrain Periaqueductal Gray Matter: Functional, Anatomical and Neurochemical Organization. Plenum Press: New York. pp 417-448.
33. Silveira M.CL, Graeff FG, Sandner G (1994). Regional distribution of Fos-like immunoreactivity in the rat brain after exposure to fear-inducing stimuli. Braz J Med Biol Res 27: 1077-1081.
34. Singewald N, Sharp T (2000). Neuroanatomical targets of anxiogenic drugs in the hindbrain as revealed by Fos immunocytochemistry. Neuroscience 98: 759-770.
35. Suh HW, Kim YH, Choi YS, Song DK (1995). Involvement of different subtypes of cholecystokinin receptors in opióide antinociception in the mouse. Peptides 16: 229-234.
36. Suh HW, Song DK, Kwon SH, Kim KW, Min BH, Kim YH (1996). Involvement of supraspinal and spinal CCK receptors in the modulation of antinociception induced by cold water swimming stress in the mouse. Neuropeptides 30: 379-384.
37. Treit D, Menard J, Royan C (1993). Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 44: 463-469.
38. Wang H, Zhu YZ, Farrok JM, Moochhala S, Teo AL, Lee LKH et al (2003). Genetic variations in CCK2 receptor in PVG Hooded and Sprague-Dawley rats and its mRNA expression on cat exposure. Behav Neurosci 117: 385-390.